OrthoPediatrics (NASDAQ:KIDS) CFO Buys $98,525.16 in Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) CFO Fred Hite purchased 5,076 shares of the company’s stock in a transaction on Thursday, August 21st. The stock was purchased at an average price of $19.41 per share, for a total transaction of $98,525.16. Following the purchase, the chief financial officer directly owned 213,065 shares of the company’s stock, valued at $4,135,591.65. This trade represents a 2.44% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

OrthoPediatrics Stock Performance

Shares of NASDAQ:KIDS traded up $0.51 during trading hours on Monday, hitting $20.71. The stock had a trading volume of 39,554 shares, compared to its average volume of 197,282. The stock’s fifty day simple moving average is $21.04 and its 200 day simple moving average is $22.21. OrthoPediatrics Corp. has a 1-year low of $16.59 and a 1-year high of $33.14. The firm has a market capitalization of $519.28 million, a price-to-earnings ratio of -11.56 and a beta of 1.12. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.43 and a current ratio of 6.66.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.06. OrthoPediatrics had a negative net margin of 18.92% and a negative return on equity of 6.36%. The company had revenue of $61.08 million for the quarter, compared to analyst estimates of $61.40 million. OrthoPediatrics has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KIDS has been the topic of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $42.00 price objective on shares of OrthoPediatrics in a research note on Thursday, May 8th. JMP Securities set a $35.00 price objective on shares of OrthoPediatrics and gave the company a “market outperform” rating in a research note on Friday, August 8th. BTIG Research lowered their price objective on shares of OrthoPediatrics from $40.00 to $39.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. Piper Sandler lowered their price objective on shares of OrthoPediatrics from $40.00 to $30.00 and set an “overweight” rating on the stock in a research note on Thursday, May 8th. Finally, Citigroup reiterated a “market outperform” rating on shares of OrthoPediatrics in a research note on Friday, August 8th. Seven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, OrthoPediatrics presently has an average rating of “Moderate Buy” and an average target price of $34.14.

Hedge Funds Weigh In On OrthoPediatrics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. lifted its holdings in shares of OrthoPediatrics by 3.0% in the fourth quarter. Invesco Ltd. now owns 16,363 shares of the company’s stock valued at $379,000 after purchasing an additional 469 shares in the last quarter. Northern Trust Corp raised its position in OrthoPediatrics by 0.3% during the fourth quarter. Northern Trust Corp now owns 193,798 shares of the company’s stock valued at $4,492,000 after buying an additional 644 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in OrthoPediatrics by 6.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after buying an additional 645 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its position in OrthoPediatrics by 12.4% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,901 shares of the company’s stock valued at $342,000 after buying an additional 1,753 shares during the period. Finally, Wells Fargo & Company MN raised its position in OrthoPediatrics by 31.1% during the fourth quarter. Wells Fargo & Company MN now owns 9,853 shares of the company’s stock valued at $228,000 after buying an additional 2,338 shares during the period. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.